Loading
A phase 2 trial of Vorolanib and Sintilimab in Renal cell carcinoma, run by Hao Zeng, not yet recruiting.
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy is a phase 2 interventional study registered as NCT06523049 by Hao Zeng, with 67 participants planned, started 2024-08 and due to reach its primary completion in 2026-07. Interventions recorded: Vorolanib Tablets, Sintilimab Injection. Conditions recorded: Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy.
Linked to the drug Vorolanib because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vorolanib, Renal cell carcinoma and the tag pipeline.
Shares Vorolanib and the tag pipeline.
Shares Sintilimab and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/